
03:25 ET MLTX Investors Have Opportunity to Lead MoonLake Immunotherapeutics Securities Fraud Lawsuit with the Schall Law Firm

I'm PortAI, I can summarize articles.
The Schall Law Firm has initiated a class action lawsuit against MoonLake Immunotherapeutics for securities fraud, alleging false and misleading statements about its drug candidate, sonelokimab. Investors who purchased shares between March 10, 2024, and September 29, 2025, are encouraged to join the lawsuit by December 15, 2025. The lawsuit claims MoonLake's public statements were misleading, leading to significant investor losses.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.

